Literature DB >> 32556805

Minimally invasive resection of intracranial lesions using tubular retractors: a large, multi-surgeon, multi-institutional series.

Daniel G Eichberg1,2, Long Di3, Ashish H Shah3, Evan M Luther3, Christina Jackson4, Lina Marenco-Hillembrand5, Kaisorn L Chaichana5, Michael E Ivan3,6, Robert M Starke3, Ricardo J Komotar3,6.   

Abstract

PURPOSE: Lesions located in subcortical areas are difficult to safely access. Tubular retractors have been increasingly used successfully with low complication profile to access lesions by minimizing brain retraction trauma and distributing pressure radially. Both binocular operative microscope and monocular exoscope are utilized for lesion visualization through tubular retractors. We present the largest multi-surgeon, multi-institutional series to determine the efficacy and safety profile of a transcortical-transtubular approach for intracranial lesion resections with both microscopic and exoscopic visualization.
METHODS: We reviewed a multi-surgeon, multi-institutional case series including transcortical-transtubular resection of intracranial lesions using either BrainPath (NICO, Indianapolis, Indiana) or ViewSite Brain Access System (VBAS, Vycor Medical, Boca Raton, Florida) tubular retractors (n = 113).
RESULTS: One hundred thirteen transtubular resections for intracranial lesions were performed. Patients presented with a diverse number of pathologies including 25 cavernous hemangiomas (21.2%), 15 colloid cysts (13.3%), 26 GBM (23.0%), two meningiomas (1.8%), 27 metastases (23.9%), 9 gliomas (7.9%) and 9 other lesions (7.9%). Mean lesion depth below the cortical surface was 4.4 cm, and mean lesion size was 2.7 cm. A gross total resection was achieved in 81 (71.7%) cases. Permanent complication rate was 4.4%. One patient (0.8%) experienced one early postoperative seizure (< 1 week postop). No patients experienced late seizures (> 1 week follow-up). Mean post-operative hospitalization length was 4.1 days.
CONCLUSION: Tubular retractors provide a minimally invasive operative corridor for resection of intracranial lesions. They provide an effective tool in the neurosurgical armamentarium to resect subcortical lesions with a low complication profile.

Entities:  

Keywords:  Brain tumor; Exoscope; Microsurgery; Minimally invasive surgery; Neurosurgery; Tubular retractor

Mesh:

Year:  2020        PMID: 32556805     DOI: 10.1007/s11060-020-03500-0

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  35 in total

1.  Stereotactic microsurgical craniotomy for the treatment of third ventricular colloid cysts.

Authors:  K L Cabbell; D A Ross
Journal:  Neurosurgery       Date:  1996-02       Impact factor: 4.654

2.  Endoscopic transtubular resection of a colloid cyst.

Authors:  Abdulrazag M Ajlan; Maziyar A Kalani; Griffith R Harsh
Journal:  Neurosciences (Riyadh)       Date:  2014-01       Impact factor: 0.906

3.  Microsurgical removal of intraventricular lesions using endoscopic visualization and stereotactic guidance.

Authors:  Anthony E Harris; Costas G Hadjipanayis; L Dade Lunsford; Andrew K Lunsford; Amin B Kassam
Journal:  Neurosurgery       Date:  2005-01       Impact factor: 4.654

4.  An extent of resection threshold for newly diagnosed glioblastomas.

Authors:  Nader Sanai; Mei-Yin Polley; Michael W McDermott; Andrew T Parsa; Mitchel S Berger
Journal:  J Neurosurg       Date:  2011-03-18       Impact factor: 5.115

5.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival.

Authors:  M Lacroix; D Abi-Said; D R Fourney; Z L Gokaslan; W Shi; F DeMonte; F F Lang; I E McCutcheon; S J Hassenbusch; E Holland; K Hess; C Michael; D Miller; R Sawaya
Journal:  J Neurosurg       Date:  2001-08       Impact factor: 5.115

6.  An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity.

Authors:  Mark E Oppenlander; Andrew B Wolf; Laura A Snyder; Robert Bina; Jeffrey R Wilson; Stephen W Coons; Lynn S Ashby; David Brachman; Peter Nakaji; Randall W Porter; Kris A Smith; Robert F Spetzler; Nader Sanai
Journal:  J Neurosurg       Date:  2014-01-31       Impact factor: 5.115

7.  Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.

Authors:  Orin Bloch; Seunggu J Han; Soonmee Cha; Matthew Z Sun; Manish K Aghi; Michael W McDermott; Mitchel S Berger; Andrew T Parsa
Journal:  J Neurosurg       Date:  2012-10-05       Impact factor: 5.115

Review 8.  Reoperation for recurrent high-grade glioma: a current perspective of the literature.

Authors:  Shawn L Hervey-Jumper; Mitchel S Berger
Journal:  Neurosurgery       Date:  2014-11       Impact factor: 4.654

9.  Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery.

Authors:  Nicholas F Marko; Robert J Weil; Jason L Schroeder; Frederick F Lang; Dima Suki; Raymond E Sawaya
Journal:  J Clin Oncol       Date:  2014-02-10       Impact factor: 44.544

10.  Multiple resections for patients with glioblastoma: prolonging survival.

Authors:  Kaisorn L Chaichana; Patricia Zadnik; Jon D Weingart; Alessandro Olivi; Gary L Gallia; Jaishri Blakeley; Michael Lim; Henry Brem; Alfredo Quiñones-Hinojosa
Journal:  J Neurosurg       Date:  2012-10-19       Impact factor: 5.115

View more
  3 in total

1.  Publisher's Note.

Authors: 
Journal:  J Neurooncol       Date:  2021-02       Impact factor: 4.130

Review 2.  The Exoscope in Neurosurgery: An Overview of the Current Literature of Intraoperative Use in Brain and Spine Surgery.

Authors:  Nicola Montemurro; Alba Scerrati; Luca Ricciardi; Gianluca Trevisi
Journal:  J Clin Med       Date:  2021-12-31       Impact factor: 4.241

3.  Cerebral corridor creator for resection of trigone ventricular tumors: Two case reports.

Authors:  Xing-Wu Liu; Wei-Rong Lu; Tian-Yi Zhang; Xu-Sheng Hou; Zhi-Qiang Fa; Shi-Zhong Zhang
Journal:  World J Clin Cases       Date:  2022-02-26       Impact factor: 1.337

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.